Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy

L. Dirven, N.B. Klarenbeek, M. van den Broek, J.H.L.M. Groenendael, P.B.J. de Sonnaville, P.J.S.M. Kerstens, T.W.J. Huizinga, B.A.C. Dijkmans, W.F. Lems, C.F. Allaart

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)585-590
JournalClinical Rheumatology
Volume32
Issue number5
DOIs
Publication statusPublished - 2013

Cite this

Dirven, L., Klarenbeek, N. B., van den Broek, M., Groenendael, J. H. L. M., de Sonnaville, P. B. J., Kerstens, P. J. S. M., ... Allaart, C. F. (2013). Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Clinical Rheumatology, 32(5), 585-590. https://doi.org/10.1007/s10067-012-2136-8